Robin Shane Readnour, Director at AN2 Therapeutics, Inc. (ANTX), sold 1,108 shares at $6.02 ($7K) on 2026-09-09, disclosed to the SEC on 2026-09-11.
Scheduled sale ($7k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $6.02 | 523 | $3K | 47.2% |
| 2 | $6.02 | 585 | $4K | 52.8% |
| Total | $6.02 avg | 1,108 | $7K | 100% |
| Filing → |
| ANTX | BUY | 2024-12-10 | $79K | — | Filing → |
| ANTX | BUY | 2024-11-27 | $53K | — | Filing → |
| ANTX | BUY | 2024-11-21 | $213K | — | Filing → |